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Acute renal failure independently predicts mortality after
myeloablative allogeneic hematopoietic cell transplant.
Background. Patients undergoing myeloablative allogeneic
hematopoietic cell transplantation (HCT) have a high incidence
of acute renal failure (ARF). However, it is unclear if ARF is
independently associated with mortality after this procedure.
Methods. We performed meta-analysis of published reports
on ARF after myeloablative allogeneic HCT. Four databases
(MEDLINE, Cochrane Library, PubMed, Web of Science) and
hand searching of conference proceedings were used to identify
the studies. ARF was defined as the doubling of serum creati-
nine occurring within the first 100 days after HCT. The absolute
and the relative risks for death after ARF were calculated for
every study. The combined relative risk was calculated using
the random effects model. Also, multivariate analysis of pa-
tient level data was performed on patients from The University
of Colorado to establish independent association between ARF
and mortality.
Results. One thousand two hundred and eleven patients were
included in the meta-analysis from the 6 published reports
in the literature. The overall incidence of ARF varied from
42% to 84% in these studies. On combining the studies by
random-effects model, the relative risk of death after ARF was
2.22 (95%CI 1.38–3.5, P < 0.001). The analysis of patient level
data from the University of Colorado demonstrated increas-
ing mortality with worsening grades of ARF. After controlling
for various demographic and clinical variables with logistic re-
gression, patients who required dialysis had a 6.8-fold higher
association with mortality.
Conclusion. ARF appears to independently influence mortal-
ity after myeloablative allogeneic HCT. Future studies should
be aimed at interventions that can reduce the incidence and
severity of ARF with this procedure.
Acute renal failure (ARF) is a serious medical compli-
cation among intensive care unit (ICU) patients, and is
associated with poor outcomes and increased resource
utilization [1–4]. ARF frequently occurs in particular
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patient subgroups of the ICU as follows: 51% after liver
transplantation, 12%–18% after aortic surgery, and 1%
to 8% after cardiac surgery [5–7]. ARF usually occurs as
a consequence of septic, toxic, or ischemic insults in the
ICU [8]. Patients admitted for myeloablative allogeneic
hematopoietic cell transplantation (HCT) are similar to
ICU patients as they are critically ill and frequently have
multiorgan failure. Because of these similarities, ARF oc-
curs with an exceedingly high frequency after myeloabla-
tive HCT. If ARF is defined as the doubling of serum
creatinine, the reported incidences of ARF vary from
21% to 69% after myeloablative allogeneic HCT [9–11].
A smaller percentage of patients, approximately 10% to
30%, develop ARF that is severe enough to require dial-
ysis [9–11]. Despite the improved outcomes with HCT,
and the advances in intensive care and dialysis therapies,
mortality in patients who develop ARF after HCT, and
the number of patients requiring dialysis, remains alarm-
ingly high.
Although ARF potentially is a fully reversible process,
many of these patients die prior to renal recovery. In the
largest published study to date, Metnitz et al, analyzing
data from over 17,000 patients admitted to the ICU in
Austria, showed that ARF was associated with a greater
than 4-fold increase in mortality after controlling for un-
derlying severity of illness [4]. Along with this study, com-
pelling studies by Levy et al and Chertow et al argue that
patients who develop ARF are at an additional increased
risk of death in some way related to renal failure itself
[12, 13]. It is unknown if ARF independently influences
the outcomes in myeloablative allogeneic HCT. In con-
trast, some investigators believe that ARF occurs due
to the preexisting comorbid conditions, and that these
conditions themselves also lead to other nonrenal com-
plications and multiorgan dysfunction, resulting in death
[14]. This distinction is critical for HCT, because if ARF
is only an epiphenomenon, then little benefit would be
derived from interventions to prevent or alter the course
of ARF [13]. Conversely, if ARF is an independent pre-
dictor of mortality, therapies that prevent or treat ARF
may substantially improve HCT outcomes.
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We hypothesize that ARF is an independent predictor
of mortality after myeloablative allogeneic myeloablative
HCT. We have attempted to substantiate our hypothesis
with 2 different approaches. First, we summarized the ex-
isting studies that have reported on ARF after allogeneic
myeloablative HCT and have performed a meta-analysis
of the reported results. Second, we analyzed the patient
level data and explored this question in the cohort of pa-
tients who received myeloablative allogeneic HCT at our
institution.
METHODS
Meta-analysis of studies on ARF after myeloablative
allogeneic HCT
Selection of studies and literature search. This meta-
analysis was performed according to a predetermined
protocol after the recommendations of the quality of re-
porting of the meta-analysis statement [15]. The primary
goal for the literature search was to find the studies that
have described ARF in the setting of myeloablative allo-
geneic HCT in humans older than 18 years. An indepen-
dent review of citations from MEDLINE (OVID 1966 to
October 2003), the Cochran database, and the PubMed
bibliographic database was conducted. The search strat-
egy that was developed with the assistance of an
experienced librarian used terms most sensitive for
identifying studies of epidemiology and prognosis [16].
The search strategy included the terms bone marrow
transplant, hematopoietic cell transplant, renal failure,
kidney disease, renal dysfunction, hypertension, and pro-
teinuria (complete strategy available on request). We also
searched the “Related Articles” feature in PubMed. Full
text articles were retrieved if any of the authors consid-
ered any citation potentially relevant. The studies with
less than 50 patients were excluded. The relevant arti-
cles were also cross-referenced using the Web of Sci-
ence (product developed by the Institute for Scientific
Information), which is a citation database. In a citation
database, a document’s historic origin (the cited refer-
ences) can be traced to the document’s current position
in the literature (times cited). Supplementary methods
of finding the studies included a review of American
Society of Nephrology and American Society of Hema-
tology meeting abstracts from last 5 years. Studies may
have been published in full or abstract format in the En-
glish language. The assessment of abstracts from proceed-
ings and published articles by the same investigator or
from the same institution was critically appraised to avoid
duplication.
Data abstraction. ARF was defined as the doubling
of serum creatinine or the decrease in GFR by 50%, oc-
curring in the first 100 days after the HCT. Survival was
recorded at 6 months. Data abstracted included the type
of observational study, the type of HCT, the number of pa-
tients in the study, the duration of follow-up, patients with
ARF, and survival information. Data abstraction was ver-
ified twice independently before further analysis. When
data for primary analysis were not readily available from
the article, the respective authors were contacted for fur-
ther information.
Quantitive data synthesis. For every study, we calcu-
lated the relative risk (RR) for the primary outcome. The
Q statistic was calculated to assess if significant hetero-
geneity was present between the included studies. For
P values less than 0.1, this assumption was deemed invalid
[17]. Since the Q statistic indicated that significant hetero-
geneity was present, we used the random-effects model to
combine the effect sizes of the included studies [18]. This
model is generally more conservative because it considers
“between-study” differences in its calculations. This leads
to wider confidence intervals when a given level of het-
erogeneity in treatment effect is observed. To test the ro-
bustness of our findings to different assumptions, we also
combined the effect sizes of all studies with the fixed-
effects model [19]. We assessed for the presence of pub-
lication bias with a funnel plot for asymmetry—a scatter
plot of studies that relates the magnitude of the treat-
ment effect against a measure of precision [20]. The
statistical analysis was performed using comprehensive
meta-analysis software (Biostat, Inc., Englewood, NJ,
USA).
Analysis of the study cohort who received myeloablative
allogeneic HCT at UCHSC
Patients. Data were collected on 88 consecutive pa-
tients who underwent myeloablative allogeneic HCT at
The University of Colorado Health Sciences Center from
1995 to 2000. The detailed demographic and clinical char-
acteristics, including details regarding their HCT, are
available in our previously published report [9].
Variables. Mortality at 6 months was our primary out-
come variable. Renal function was assessed by the serum
creatinine concentration and an estimated GFR calcu-
lated by the MDRD equation [GFR (mL/min/1.73m2) =
186 × Pcr−1.154 × age−0.203 × 1.212 if black × 0.742 if fe-
male] [21]. ARF was divided into 4 categories as follows:
grade 0, or normal renal function, was equivalent to a de-
crease in estimated GFR of less than 25% of the baseline
value. Grade 1 ARF corresponded to less than a 2-fold
rise in serum creatinine concentration, with a decrease
in estimated GFR of greater than 25% of the baseline
value. Grade 2 ARF corresponded to greater than a 2-fold
rise in serum creatinine concentration of the baseline
value, but not requiring dialysis. Grade 3 ARF corre-
sponded to patients with grade 2 parameters and requir-
ing dialysis. This classification of grades of ARF is similar
to other published studies in the setting of HCT [9, 11,
22].
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Table 1. Summary of studies on ARF in allogeneic myeloablative HCT
Study Zager et al Gruss et al Ratanatharathorn et al Letourneau et al Nash et al Parikh et al
Study period 1986 1982–91 1993–1994 1994–98 1995–1996 1995–2000
Country USA Spain USA Canada USA USA
Patients in the study 272 275 332 57 180 88
Autologous/allogeneic 11%/91% 33%/67% 0%/100% 26%/73% 0%/100% 0%/100%
ARF in auto/ARF in allo 39%/54% 6.5%/36% 0%/76% 60%/79% 0%/80% 0%/69%
Death in patients without ARF 17% 18% 20% 60% 30% 40%
Death in patients with ARF 58% 46% 43% 88% 42% 66%
Death in patients with dialysis 84% 89% 95% 100% 94% 83%
It is evident that the mortality in patients who develop ARF is much higher than in patients who do not develop ARF. Patients who require dialysis have mortality >80%.
The other independent variables that were included
in the analysis were demographic variables (age, gender,
race) and variables from the clinical course [baseline ma-
lignancy, conditioning regimen with cyclophosphamide
or total body irradiation (TBI), sepsis, liver function
tests, antibiotic use, and hepatic veno-occlusive disease
(VOD)].
Statistical analysis. For univariate analysis, continuous
variables were analyzed using the t test or the Wilcoxon
rank-sum test where appropriate. Categorical variables
were expressed as proportions and compared with the
Mantel-Haenszel chi-square test. Variables with signifi-
cant associations on univariate screening were considered
candidates for multivariable analysis. Logistic regression
was employed for multivariate analysis for calculating
adjusted odds ratios. We used the Kaplan-Meier prod-
uct limit method to calculate time to death for various
grades of ARF. The survival curves were compared with
the log-rank test. P ≤ 0.05 (two-tailed) was considered
statistically significant. All analyses were conducted us-
ing SAS statistical software, version 8.3 (SAS Institute,
Inc., Cary, NC, USA).
Study conduct. The study was approved by the
Colorado Institutional Review Board.
RESULTS
Summary and meta-analysis of existing literature
We found 6 published reports that described ARF af-
ter myeloablative allogeneic HCT that fulfilled all of the
inclusion criteria [9–11, 23–25]. There were 5 studies that
could not be included because they studied only ARF
requiring dialysis, did not have complete information on
the patients who did not develop ARF, or had redundant
data [26–30]. The definition of ARF varied in these stud-
ies. However, for the purposes of this meta-analysis, ARF
is uniformly defined as the doubling of serum creatinine
from baseline. In Table 1 are summarized the details of
these 6 studies. Two of the 6 observational studies had
prospective data collection [24, 25]. The 2 prospective
studies were multicenter studies, and the remaining re-
ports were single-center studies. The number of patients
in these studies ranged from 57 to 332, and the study pe-
riod ranged from 2 to 9 years.
The case mix is diverse because the patients of
myeloablative autologous and allogeneic transplants are
combined in the older studies [10, 11, 23]. There are
only 3 studies that specifically reported on myeloabla-
tive allogeneic HCT [9, 24, 25]. Although the studies are
performed during varying time periods and on different
continents, there is one unifying message evident from
the Table: patients with ARF have 2- to 3-fold higher
mortality than patients who do not develop ARF. Fur-
thermore, patients who require dialysis have mortality
that is uniformly >80%.
A total of 1211 patients were available from these 6
studies. Relative risk (RR) for death after development
of ARF was calculated for each of the individual studies.
As all of the studies had a cohort study design, we de-
cided to do RR estimation as opposed to an odds ratio
(OR). RR is also a more accurate estimate of the risk
as opposed to OR. In Table 2 is shown the individual
and absolute relative risks in each trial. In the majority
of the studies there was a significant increase in RR for
death after the development of ARF [10, 11, 24, 25]. The
data on myeloablative allogeneic HCT were not available
separately for the studies that have reported on combined
autologous and allogeneic HCT. The Q statistic indicated
significant heterogeneity between the studies (P < 0.01).
In the present study, 56% (400 of 712) of patients who
developed ARF died, as opposed to 20% (100 of 499)
who did not develop ARF. When the effect sizes of these
6 studies were combined using the random-effects model,
a significant increase in RR of death by 2.22-fold after
the development of ARF was seen (P < 0.01, Fig. 1). The
fixed-effects model yielded a RR of 2.65 (CI −2.19–3.19,
P < 0.01). Funnel plotting of the standard error of the
log RR versus the log relative risk showed asymmetry,
suggesting the presence of publication bias.
The study by Zager et al that was performed in 1989 was
the oldest among all the observational studies, and also
had the highest RR for death after development of ARF.
The results of the meta-analysis changed only slightly af-
ter excluding this study. The fixed- and the random-effects
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Table 2. Individual and absolute relative risks for mortality
Citation Year ARF No ARF Relative risk 95% CI
Spain–Gruss 1991 33/72 (45%) 36/203 (18%) 2.58 (1.75–3.81)
Canada–Letourneau 1998 37/42 (88%) 9/15 (60%) 1.5 (0.96–2.25)
USA–Nash 2000 60/143 (42%) 11/37 (30%) 1.4 (0.83–2.40)
USA–Parikh 2000 40/61 (65%) 11/27 (40%) 1.6 (0.99–2.63)
USA–Ratanatharathorn 1998 109/251 (43%) 16/78 (20%) 2.12 (1.34–3.35)
USA–Zager 1986 121/143 (84%) 17/129 (13%) 6.42 (4.1–10.0)
Values are number of patients who died/number of patients at risk (%).
Fixed
Random
Citation
Gruss
Letourneau
Nash
Parikh
Ratanatharathorn
Zager
Combined (6)
Combined (6)
Effect
2.584
1.468
1.411
1.610
2.117
6.421
2.650
2.225
Lower
1.753
.957
.829
.986
1.338
4.101
2.195
1.387
Upper
3.811
2.252
2.401
2.627
3.351
10.054
3.198
3.570
0.1 0.2 0.5 1 2 5 10
No death Death
Forest plot
Fig. 1. Association of ARF with mortality at 6 months for all 6 studies. Data are calculated by the random-effects model and the fixed-effects
model. Dark circles are relative risks, lines are 95% CI. The vertical solid line indicates no effect of ARF on mortality; values greater than 1 indicate
ARF associated with death.
model estimated a RR of 1.9 (CI 1.5–2.4, P < 0.01) and
1.83 (CI 1.4–2.3, P < 0.01), respectively, after excluding
the Zager study.
Results from University of Colorado
A study was undertaken at the University of Colorado
to evaluate the occurrence and the severity of renal injury
in 88 patients receiving myeloablative allogeneic HCT
[9]. The mean age of the patients was 38.7 years, and
60% of them were female. The hematopoietic cell sup-
port included bone marrow or peripheral stem cells from
related donors in 50% of patients, and from unrelated
donors in 17% of donors. Umbilical cord blood was used
as a source of hematopoietic progenitor cells in the re-
maining 33% of patients. The baseline characteristics,
type of conditioning regimen, immunosuppression, and
anti-infective prophylaxis in this cohort previously have
been described [9]. The mean baseline estimated GFR
was 106 ± 30 mL/min/1.73 m2 for the whole cohort. There
were no differences in the baseline GFR when separated
by gender, conditioning regimen, or mortality [9].
Of the 88 patients, 81 (92%) had a decrease in esti-
mated GFR (i.e., grade 1–3) after myeloablative allo-
geneic HCT. When considering only severe renal dysfunc-
tion (grades 2 and 3), 69% of patients had a significant
decline in renal function. The overall rate of mortality at
6 months for the myeloablative allogeneic HCT was 58%
(51 of 88 patients). The predominant causes of death in
these patients were drug (chemotherapy or immunosup-
pression) toxicity (33%), infection (30%), tumor progres-
sion (17%), graft versus host disease (5%), and bleeding
(5%). The grade 3 patients, who required dialysis, had a
very high mortality of 82.7%. Among the grade 3 patients,
60% of the patients were initiated on continuous dialy-
sis, and 40% were started on intermittent dialysis. The
dialysis modality was frequently interchanged based on
patient’s cardiovascular status. There was no difference
in mortality in patients who were initiated on continu-
ous versus intermittent dialysis. Figure 2 demonstrates
that the association of the 3 grades of renal failure with
6-month mortality is significant (log-rank test, P < 0.05).
The multivariate analysis associating grade 3 ARF with
mortality at 6 months after myeloablative HCT is demon-
strated in Table 3. The logistic regression models were ad-
justed for potential confounders. The unadjusted odds of
association of grade 3 ARF with mortality are 8.6. After
controlling for various demographics, HCT, and clinical
variables, the odds of association of grade 3 ARF with
mortality decrease modestly. The adjusted odds of mor-
tality with dialysis are 6.8-fold higher after controlling for
other important variables, suggesting that grade 3 ARF
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Fig. 2. Kaplan-Meier survival graph demonstrating association of
grades of ARF with mortality.
Table 3. Multivariate logistic regression model examining odds ratios
associated with grade 3 ARF (dialysis) and 6-month mortality
Model Odds ratios 95% CI
Unadjusted 8.6 2.4–30.5
Adjusted for
Demographic variables 7.6 2.2–25.7
Demographic variables and HCT
variables
5.4 1.8–26.2
Demographic variables, HCT
variables, and clinical variables
6.8 1.6–28.6
Demographic variables: age, gender, and race. HCT variables: type of
malignancy (aggressive vs. indolent), source of donor cells (peripheral blood,
umbilical cord, and bone marrow), total body irradiation, cyclophosphamide
therapy, and type of donor (related vs. unrelated). Clinical variables: sepsis,
veno-occlusive disease of liver, liver function tests, antifungal and aminoglycoside
use.
is an independent predictor of death after myeloablative
allogeneic HCT.
DISCUSSION
Since its inception in 1970s, the indications for
myeloablative allogeneic HCT have expanded to in-
clude several otherwise incurable malignancies and
autoimmune diseases. Annually, approximately 15,000
myeloablative allogeneic HCT procedures are performed
worldwide, with more than 50% of them being performed
in U.S. (www.ibmtr.org). Survival after myeloablative al-
logeneic HCT depends on recovery from the effects of cy-
toreductive therapy, successful engraftment, prevention
and treatment of infections and graft-versus-host disease,
and eradication of the underlying disease. Transplant-
related organ-dysfunctions of the liver, the lung, and the
kidney are a major cause of morbidity and mortality as-
sociated with this procedure. ARF occurring early in the
course of myeloablative allogeneic HCT is rarely tran-
sient, and may require renal replacement therapy. Con-
sidering the frequency of the complications, relatively few
data are available regarding the mortality rates associated
with ARF in HCT.
In our meta-analysis combining the results of 6 co-
hort studies in myeloablative allogeneic HCT through
a random-effects model, we recorded a doubling in rela-
tive risk [RR 2.31; CI (1.47–3.65), P < 0.01] of death in
patients who had at least a doubling of serum creatinine
from baseline (grades 2 and 3). The results of the meta-
analysis were robust, as similar results were obtained
after the fixed-effects model [RR 2.72, CI (2.25–3.29),
P < 0.01]. It is not well established which statistical model
is most appropriate to combine the relative risk of dif-
ferent studies. However, if the statistical heterogeneity is
present between studies, as in our present analysis, the use
of random-combined models is generally recommended.
The heterogeneity in the studies is not surprising as there
was considerable variability in the procedure and time
period of allogeneic HCT. For example, the older stud-
ies mainly used methotrexate and prednisone for graft-
versus-host disease prophylaxis, while the newer studies
employed calcineurin inhibitors, such as cyclosporine and
tacrolimus. The recent study cohorts also have a higher
number of patients with unrelated donors and use of pe-
ripheral blood and umbilical cord–derived stem cells. The
use of anti-infective prophylaxis also differs due to the de-
creased use of nephrotoxic antibiotics and increased use
of antiviral agents.
Nevertheless, the analysis of patient level data at the
University of Colorado demonstrates that dialysis requir-
ing ARF (grade 3) is independently associated with mor-
tality after adjusting for various demographic and clinical
variables. The patients who required dialysis had more
than 6-fold higher odds of mortality. The mortality rate
among patients with ARF in this study is very high and the
OR changed only slightly with adjustments for other vari-
ables. Although the Kaplan-Meier analysis shows clear
separation of the 3 survival curves (Fig. 2), the quanti-
tative relation of all 3 grades of ARF to mortality could
not be established due to small sample size and lack of
statistical power. The mortality rates in the HCT popula-
tion have consistently exceeded those observed in general
ICU patients with respect to use of dialysis to treat ARF
[4, 31, 32]
The increased mortality associated with ARF may
be explained either by disturbances in physiologic and
immunologic functions that are deranged with ARF,
or by potential side effects due to renal replacement
therapy. It is well known that ARF often leads to nu-
merous problems for the patient, including metabolic
acidosis, cardiac dysrythmias, hypertension, electrolyte
imbalances, gastrointestinal dysfunction, bleeding, infec-
tion, volume overload, and pulmonary edema [8]. Vol-
ume overload due to poor sodium and water excretion is
a major problem with early ARF. Volume overload may
lead to pulmonary congestion with increased need for
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mechanical ventilation, which further predisposes to in-
fection and septicemia [33]. Although theoretically ure-
mia and volume problems may be alleviated after initia-
tion of dialysis, several metabolic and immunologic prob-
lems persist and cumulatively contribute to mortality de-
spite the use of dialysis [34]. An increase in the oxidant
stress has been implicated in the evolution and mainte-
nance of tissue injury in critically ill patients [35]. It is
also plausible that the reason for increased mortality is
not ARF itself, but the ARF management strategies. For
example, hemodialysis can cause systemic hypotension
and may induce injury to the kidney as well as other or-
gans [36].
In order to improve the mortality associated with ARF
several strategies may be employed. The early involve-
ment of nephrologists in the care of patients receiving
HCT may be necessary [37]. Guidelines for timing, dose
duration, and modality of dialysis for ARF in the setting
of HCT are clearly needed. Perhaps the most contentious
issue is whether the mode of dialysis should be continu-
ous or intermittent. There were not enough patients in
the present study to make this distinction. Also, conduct-
ing studies with selective interventions for treatment or
prevention of ARF after HCT are needed to decrease the
incidence and severity of ARF [8]. Patients receiving al-
logeneic HCT may be an important group for conducting
clinical trials in ARF for the following reasons. They are
a captive population similar to the patients in the ICU,
the timing of the ARF is predictable, and the ARF event
rates are relatively high, allowing sample size feasibility.
Toward this goal we have initiated a Phase II study for
prevention of ARF after myeloablative allogeneic HCT
with selective renal vasodilator urodilatin and mannitol
[38].
Our study has several limitations that should be taken
into account. First, publication bias is always a poten-
tial limitation in a meta-analysis. Negative studies are not
published because they have not been submitted or ac-
cepted for publication. We attempted to account for this
limitation by including abstracts in our search strategy
because negative studies may be more likely to remain
unpublished after being presented in abstract form [39].
Second, the studies included in this meta-analysis are het-
erogenous with respect to time of enrollment, immuno-
suppression, and underlying malignancies. However, our
findings are consistent with the notion that physicians are
more likely to encounter heterogeneity in clinical prac-
tice. Third, this meta-analysis is limited to summary mea-
sures of unadjusted relative risks of ARF causing mor-
tality. Although a pooled analysis of individual patient
data for all the studies was not possible, we have ana-
lyzed the patient level data from University of Colorado
to enable the adjustment of analyses for variables that
may potentially confound this relationship. Finally, the
limitation related to the multivariate data analysis is due
to the effect of residual confounding on the final asso-
ciation of dialysis and mortality. Although the analysis
adjusted for several important risk factors like sepsis and
hepatic VOD, there may be other variables that are dif-
ficult to measure and were not accounted in the analysis.
However, the adjusted OR of 6.8 signifies a strong re-
lationship and would be difficult to negate completely,
despite controlling for other factors.
CONCLUSION
Within the limits of observational study design, pa-
tients appear to die of ARF, and not simply with ARF in
the setting of myeloablative HCT. Renal function cannot
be adequately replaced by dialysis and risk of mortality
remains high. Our goal should now be to focus on how to
reduce the incidence and severity of ARF and the risk of
death associated with ARF in this important subgroup of
hospitalized patients.
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